摘要
目的:观察榄香烯注射液联合TACE治疗晚期原发性肝癌的临床疗效及其不良反应。方法:将符合纳入标准的68例Ⅲ~Ⅳ期原发性肝癌患者随机分为2组各34例。治疗组接受榄香烯注射液联合TACE介入治疗,对照组接受单纯TACE治疗。对2组患者进行为期1年的随访,记录治疗经过、近期疗效、远期疗效(患者总生存期),治疗前后肿瘤指标甲胎蛋白(AFP)、评估卡氏评分(KPS),观察并记录治疗过程中的不良反应。结果:总有效率治疗组82.35%,对照组55.88%,2组临床近期疗效比较,差异有统计学意义(P<0.05)。治疗后,2组血清AFP均下降,与治疗前比较,差异均有统计学意义(P<0.05);2组比较,差异有统计学意义(P<0.05)。治疗后,2组KPS评分均升高,2组间KPS评分比较,差异均有统计学意义(P<0.05);治疗组中位生存时间11.2月,3月、6月、9月和1年的总生存率分别为95.8%、84.1%、62.3%及42.5%,对照组中位生存时间8.9月,3月、6月、9月和1年的总生存率分别为87.0%、56.8%、41.2%及28.6%,2组总生存期情况比较,差异均有统计学意义(P<0.05),治疗组在延长患者总生存期方面优于对照组。2组骨髓抑制及胃肠道反应,差异无统计学意义(P>0.05),均未出现Ⅳ度不良反应。结论:榄香烯注射液联合TACE治疗晚期原发性肝癌安全有效,可以有效控制肿瘤,降低肿瘤指标AFP,改善患者生活质量,延长患者的生存时间。
Objective：To observe the clinical effect and adverse reaction of elemene injection combined with transcatheter arterial chemoembolization（TACE） for late primary liver cancer. Methods： Divided 68 cases of patients with primary liver cancer at stage Ⅲ ~ Ⅳ into two groups with 34 cases in each randomly. The treatment group was treated with elemene injection combined with TACE,while the control group was only treated with TACE. Patients in two groups were followed up for 1 year. Recorded treatment procedure,recent effect,long-term effect（patients＇ overall survival） and carcinoma indexes like alpha-fetoprotein（AFP） before and after treatment. Evaluated Karnofsky performance status（KPS）. Observed and recorded adverse reaction during treatment. Results：The total effective rate was 82.35% in the treatment group,and was 55.88% in the control group, the difference being significant（P〈0.05）. After treatment, serum AFP in both groups was declined,comparing with that before treatment, the difference being significant（P〈0.05）. Significant difference was found in the comparison between two groups（P〈0.05）. After treatment, KPS scores in both groups were higher than those before treatment, the difference being significant（P〈0.05）. The median survival time was 11.2 months, and the overall3-,6-,9-month and 1-year survival rates in the treatment group were 95.8%,84.1%,62.3% and 42.5% respectively.The median survival time was 8.9 months,and the overall 3-,6-,9-month and 1-year survival rates in the control group were 87.0%,56.8%,41.2% and 28.6% respectively. Compared total survival in both groups,the difference being significant（P〈0.05）. The prolongation of survival in the treatment group was superior to that in the control group. Compared myelosuppression and gastrointestinal reaction in both groups,there being no significance in differences（P〉0.05）. There was no IV degree of adverse reaction in both groups. Conclusion：The therapy of elemene injection combined with TA
出处
《新中医》
CAS
2017年第5期87-90,共4页
New Chinese Medicine
基金
广东省建设中医药强省项目(20151045)
